Skip to main content

Peer Review reports

From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Original Submission
8 Jul 2021 Submitted Original manuscript
29 Jul 2021 Author responded Author comments - Yurong Wang
Resubmission - Version 2
29 Jul 2021 Submitted Manuscript version 2
13 Aug 2021 Reviewed Reviewer Report
19 Aug 2021 Reviewed Reviewer Report
21 Aug 2021 Reviewed Reviewer Report
23 Sep 2021 Author responded Author comments - Yurong Wang
Resubmission - Version 3
23 Sep 2021 Submitted Manuscript version 3
28 Sep 2021 Reviewed Reviewer Report
11 Oct 2021 Reviewed Reviewer Report
12 Oct 2021 Reviewed Reviewer Report
19 Oct 2021 Author responded Author comments - Yurong Wang
Resubmission - Version 4
19 Oct 2021 Submitted Manuscript version 4
25 Oct 2021 Author responded Author comments - Yurong Wang
Resubmission - Version 5
25 Oct 2021 Submitted Manuscript version 5
Publishing
27 Oct 2021 Editorially accepted
13 Nov 2021 Article published 10.1186/s12885-021-08942-x

You can find further information about peer review here.

Back to article page